Prophylactic drug intervention for preventing vascular access dysfunction: from the guidelines_West China Medical Journal

Authors：

CAO Zhengjiang , FU Ping ,  ZHOU Li

Department of Nephrology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;

Corresponding author：

ZHOU Li, Email: 446125447@qq.com

Keywords：

Chronic kidney disease; Hemodialysis; Vascular access; Guideline

DOI：

10.7507/1002-0179.202006096

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

The patency of vascular access is of great significance to hemodialysis patients. Combining with guidelines and literature associated with vascular access for dialysis in recent years, the authors interpret the effectiveness and limitations of prophylactic drug strategies, including using fish oil, anticoagulation, anti-platelet, lipid-lowering agents, etc., in order to promote the proper use of these agents in clinical practice, and improve the effect of prophylaxis and treatment of vascular access dysfunction.

Citation： CAO Zhengjiang, FU Ping, ZHOU Li. Prophylactic drug intervention for preventing vascular access dysfunction: from the guidelines. West China Medical Journal, 2020, 35(7): 775-780. doi: 10.7507/1002-0179.202006096 Copy

1.	Kukita K, Ohira S, Amano I, et al. 2011 update Japanese Society for Dialysis Therapy Guidelines of Vascular Access Construction and Repair for Chronic Hemodialysis. Ther Apher Dial, 2015, 19(Suppl 1): 1-39.
2.	Schmidli J, Widmer MK, Basile C, et al. Editor’s choice - Vascular Access: 2018 Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg, 2018, 55(6): 757-818.
3.	中国医院协会血液净化中心分会血管通路工作组. 中国血液透析用血管通路专家共识 (第 2 版). 中国血液净化, 2019, 18(6): 365-381.
4.	Lok CE, Huber TS, Lee T, et al. KDOQI Vascular Access Guideline Work Group. KDOQI clinical practice guideline for vascular access: 2019 update. Am J Kidney Dis, 2020, 75(4 Suppl 2): S1-S164.
5.	Viecelli AK, Irish AB, Polkinghorne KR, et al. Omega-3 polyunsaturated fatty acid supplementation to prevent arteriovenous fistula and graft failure: a systematic review and meta-analysis of randomized controlled trials. Am J Kidney Dis, 2018, 72(1): 50-61.
6.	Irish AB, Viecelli AK, Hawley CM, et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Intern Med, 2017, 177(2): 184-193.
7.	Viecelli AK, Pascoe EM, Polkinghorne KR, et al. Updates on baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology (Carlton), 2017, 22(10): 823-824.
8.	Lok CE, Moist L, Hemmelgarn BR, et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA, 2012, 307(17): 1809-1816.
9.	Herrington W, Emberson J, Staplin N, et al. The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection. Clin J Am Soc Nephrol, 2014, 9(5): 914-919.
10.	Young EV, Goodkin DA, Mapes DL, et al. The Dialysis Outcomes and Practice Patterns Study (DOPPS): an international hemodialysis study. Kidney Int, 2000, 57(Suppl 74): S74-S81.
11.	Gröntoft KC, Larsson R, Mulec H, et al. Effects of ticlopidine in AV-fistula surgery in uremia. Fistula Study Group. Scand J Urol Nephrol, 1998, 32(47): 276-283.
12.	Dember LM, Beck GJ, Allon M, et al. Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA, 2008, 299(18): 2164-2171.
13.	Dember LM, Kaufman JS, Beck GJ, et al. Design of the dialysis access consortium (DAC) clopidogrel prevention of early AV fistula thrombosis trial. Clin Trials, 2005, 2(5): 413-422.
14.	Kaufman JS. Antithrombotic agents and the prevention of access thrombosis. Semin Dial, 2000, 13(1): 40-46.
15.	Dixon BS, Beck GJ, Vazquez MA, et al. Effect of dipyridamole plus aspirin on hemodialysis graft patency. N Engl J Med, 2009, 360(21): 2191-2201.
16.	Abacilar AF, Atalay H, Dogan OF. Oral prostacycline analog and clopidogrel combination provides early maturation and long-term survival after arteriovenous fistula creation: a randomized controlled study. Indian J Nephrol, 2015, 25(3): 136-142.
17.	Coleman CI, Tuttle LA, Teevan C, et al. Antiplatelet agents for the prevention of arteriovenous fistula and graft thrombosis: a meta analysis. Int J Clin Pract, 2010, 64(9): 1239-1244.
18.	Crowther MA, Clase CM, Margetts PJ, et al. Low-intensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemodialysis: a randomized controlled trial. J Am Soc Nephrol, 2002, 13(9): 2331-2337.
19.	Osborn G, Escofet X, Da Silva A. Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts. Cochrane Database Syst Rev, 2008(4): CD002786.
20.	Saran R, Dykstra DM, Wolfe RA, et al. Association between vascular access failure and the use of specific drugs: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis, 2002, 40(6): 1255-1263.
21.	Kennard AL, Walters GD, Jiang SH, et al. Interventions for treating central venous haemodialysis catheter malfunction. Cochrane Database Syst Rev, 2017, 10(10): CD011953.
22.	Mozafar M, Samsami M, Sobhiyeh MR, et al. Effectiveness of aspirin on double lumen permanent catheter efficacy in ESRD. Nephrourol Mon, 2013, 5(2): 762-765.
23.	Abdul-Rahman SI, Al-Howaish AK. Warfarin versus aspirin in preventing tunneled hemodialysis catheter thrombosis: a prospective randomized study. Hong Kong J Nephrol, 2007, 9(1): 23-30.
24.	Wilkieson TJ, Alistair JI, Crowther MA, et al. Low-intensity adjusted-dose warfarin for the prevention of hemodialysis catheter failure: a randomized, controlled trial. Clin J Am Soc Nephrol, 2011, 6(5): 1018-1024.
25.	Herrington WG, Helen JN, Richard JH, et al. Does prophylactic anticoagulation reduce the risk of femoral tunneled dialysis catheter-related complications?. J Vasc Access, 2013, 14(2): 135-142.
26.	Colì L, Donati G, Cianciolo G, et al. Anticoagulation therapy for the prevention of hemodialysis tunneled cuffed catheter (TCC) thrombosis. J Vasc Access, 2006, 7(3): 118-122.
27.	魏甜甜, 李佩芸, 张凌, 等. 肾脏替代治疗血管通路位置与并发症的 Meta 分析. 华西医学, 2018, 33(7): 860-868.

1. Kukita K, Ohira S, Amano I, et al. 2011 update Japanese Society for Dialysis Therapy Guidelines of Vascular Access Construction and Repair for Chronic Hemodialysis. Ther Apher Dial, 2015, 19(Suppl 1): 1-39.
2. Schmidli J, Widmer MK, Basile C, et al. Editor’s choice - Vascular Access: 2018 Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg, 2018, 55(6): 757-818.
3. 中国医院协会血液净化中心分会血管通路工作组. 中国血液透析用血管通路专家共识 (第 2 版). 中国血液净化, 2019, 18(6): 365-381.
4. Lok CE, Huber TS, Lee T, et al. KDOQI Vascular Access Guideline Work Group. KDOQI clinical practice guideline for vascular access: 2019 update. Am J Kidney Dis, 2020, 75(4 Suppl 2): S1-S164.
5. Viecelli AK, Irish AB, Polkinghorne KR, et al. Omega-3 polyunsaturated fatty acid supplementation to prevent arteriovenous fistula and graft failure: a systematic review and meta-analysis of randomized controlled trials. Am J Kidney Dis, 2018, 72(1): 50-61.
6. Irish AB, Viecelli AK, Hawley CM, et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Intern Med, 2017, 177(2): 184-193.
7. Viecelli AK, Pascoe EM, Polkinghorne KR, et al. Updates on baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology (Carlton), 2017, 22(10): 823-824.
8. Lok CE, Moist L, Hemmelgarn BR, et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA, 2012, 307(17): 1809-1816.
9. Herrington W, Emberson J, Staplin N, et al. The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection. Clin J Am Soc Nephrol, 2014, 9(5): 914-919.
10. Young EV, Goodkin DA, Mapes DL, et al. The Dialysis Outcomes and Practice Patterns Study (DOPPS): an international hemodialysis study. Kidney Int, 2000, 57(Suppl 74): S74-S81.
11. Gröntoft KC, Larsson R, Mulec H, et al. Effects of ticlopidine in AV-fistula surgery in uremia. Fistula Study Group. Scand J Urol Nephrol, 1998, 32(47): 276-283.
12. Dember LM, Beck GJ, Allon M, et al. Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA, 2008, 299(18): 2164-2171.
13. Dember LM, Kaufman JS, Beck GJ, et al. Design of the dialysis access consortium (DAC) clopidogrel prevention of early AV fistula thrombosis trial. Clin Trials, 2005, 2(5): 413-422.
14. Kaufman JS. Antithrombotic agents and the prevention of access thrombosis. Semin Dial, 2000, 13(1): 40-46.
15. Dixon BS, Beck GJ, Vazquez MA, et al. Effect of dipyridamole plus aspirin on hemodialysis graft patency. N Engl J Med, 2009, 360(21): 2191-2201.
16. Abacilar AF, Atalay H, Dogan OF. Oral prostacycline analog and clopidogrel combination provides early maturation and long-term survival after arteriovenous fistula creation: a randomized controlled study. Indian J Nephrol, 2015, 25(3): 136-142.
17. Coleman CI, Tuttle LA, Teevan C, et al. Antiplatelet agents for the prevention of arteriovenous fistula and graft thrombosis: a meta analysis. Int J Clin Pract, 2010, 64(9): 1239-1244.
18. Crowther MA, Clase CM, Margetts PJ, et al. Low-intensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemodialysis: a randomized controlled trial. J Am Soc Nephrol, 2002, 13(9): 2331-2337.
19. Osborn G, Escofet X, Da Silva A. Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts. Cochrane Database Syst Rev, 2008(4): CD002786.
20. Saran R, Dykstra DM, Wolfe RA, et al. Association between vascular access failure and the use of specific drugs: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis, 2002, 40(6): 1255-1263.
21. Kennard AL, Walters GD, Jiang SH, et al. Interventions for treating central venous haemodialysis catheter malfunction. Cochrane Database Syst Rev, 2017, 10(10): CD011953.
22. Mozafar M, Samsami M, Sobhiyeh MR, et al. Effectiveness of aspirin on double lumen permanent catheter efficacy in ESRD. Nephrourol Mon, 2013, 5(2): 762-765.
23. Abdul-Rahman SI, Al-Howaish AK. Warfarin versus aspirin in preventing tunneled hemodialysis catheter thrombosis: a prospective randomized study. Hong Kong J Nephrol, 2007, 9(1): 23-30.
24. Wilkieson TJ, Alistair JI, Crowther MA, et al. Low-intensity adjusted-dose warfarin for the prevention of hemodialysis catheter failure: a randomized, controlled trial. Clin J Am Soc Nephrol, 2011, 6(5): 1018-1024.
25. Herrington WG, Helen JN, Richard JH, et al. Does prophylactic anticoagulation reduce the risk of femoral tunneled dialysis catheter-related complications?. J Vasc Access, 2013, 14(2): 135-142.
26. Colì L, Donati G, Cianciolo G, et al. Anticoagulation therapy for the prevention of hemodialysis tunneled cuffed catheter (TCC) thrombosis. J Vasc Access, 2006, 7(3): 118-122.
27. 魏甜甜, 李佩芸, 张凌, 等. 肾脏替代治疗血管通路位置与并发症的 Meta 分析. 华西医学, 2018, 33(7): 860-868.

West China Medical Journal

Prophylactic drug intervention for preventing vascular access dysfunction: from the guidelines

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content